Achilles Therapeutics (ACHL) Projected to Post Quarterly Earnings on Thursday

Achilles Therapeutics (NASDAQ:ACHL) is projected to issue its quarterly earnings data before the market opens on Thursday, April 3rd. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Achilles Therapeutics Price Performance

Achilles Therapeutics stock opened at $1.48 on Wednesday. Achilles Therapeutics has a 12-month low of $0.63 and a 12-month high of $1.51. The stock has a market capitalization of $60.83 million, a PE ratio of -0.90 and a beta of 1.25. The firm has a 50 day simple moving average of $1.36 and a 200-day simple moving average of $1.15.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.